Immuno-Oncology Platform

Immunotherapy has revolutionized cancer treatment by harnessing the patient's immune system to attack and eliminate cancer cells. Syngeneic mouse models have become a valuable tool for studying the mechanisms of immune response to cancer and evaluating the efficacy of immunotherapeutic agents.

We support your immuno-oncology project by profiling your drug candidates in the most relevant models. We combine anti-efficacy end points with ex vivo analyses to study the effects on immune cell infiltration.

We offer you a variety of services for in vivo characterization of immuno-oncology related questions. This includes the full service in flow cytometry analysis of immune cells from blood or tumor, cytokine-level measurements from mouse serum by ELISA or multiplex assays, and immunohistochemistry of tumor sections. Readouts to monitor tumor growth or tumor-induced changes depend on the model used.

In Vivo Models

We use cell line-derived xenograft (CDX) syngeneic tumor models for studying how cancer therapies perform in the presence of a functional immune system. Our portfolio of models has been well-characterized in their responses to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1, anti-CTLA-4). Upon request, we also offer hPBMC/HSC humanized models. For general study types and readouts, see also our oncology platform.

Flow Cytometry

We offer comprehensive panels to characterize immune cell populations for immuno-oncology and inflammatory diseases (flow cytometry).


We have established a broad panel of assays for human and mouse targets. Our tumor-infiltrating lymphocyte (TIL) panel is comprised of over 15 markers for systematic evaluation of TILs in mouse models. In addition, we offer assays for major populations of lymphocytes, macrophages, NK-cells, and B-cells. Protocols were optimized on mouse spleen and used to profile 15 different syngeneic mouse models (data on immune cell infiltration status of syngeneic mouse models are available for customers).

Read more: IHC in Biomarker Discovery

In Vitro Assays

In vivo immuno-oncology services are complemented by diverse and relevant in vitro assays.